The digital health provider has raised a £45m Series B extension and growth capital package led by Big Pi Ventures and HSBC Innovation Banking.
"Our latest funding is a testament to both our commercial performance and belief in our long-term vision for providing personalised, preventative health at scale. With the fresh conviction of Big Pi Ventures, Endeavor Catalyst and HSBC Innovation Banking – as well as the continued backing of White Star Capital and our long-term investors – we are now perfectly positioned to expand our reach, deepen our clinical capabilities, and accelerate innovation to help our patients live happier, healthier, longer lives."
Big Pi Ventures led the seed round for the cloud-native business intelligence platform, with backing from Propelling Tech Ventures and strategic angels.
"Astrato is the execution layer of the modern data stack. It connects directly to the cloud and gives teams a unified space to explore, act, and collaborate on data without duplication, IT bottlenecks, or licensing friction. Unlike legacy BI vendors pushing continuous price hikes, our usage-based model means customers only pay for what they consume, making Astrato accessible for both lean startups and global enterprises."
The funding round was led by Oxford Science Enterprises to support growth in the US and UK markets.
"We invest in companies with the potential to become leaders in their field, and that is why we’re proud to back the incredible team at Navenio on their latest fundraise. Navenio is revolutionising the way we create more efficient healthcare workplaces, through its proven technology powered platform for indoor mapping, and we are excited to continue supporting the team on the next stage of the company’s journey as they look to deliver its offering to a wider range of use cases and across new geographies."
— Heather Roxborough, senior partner of Health Tech
The medical device maker has raised fresh capital from backers including Crimson International Investment to support its global growth plans.
"We are delighted to secure further funding, as well as another strategic investor and partner to take our pioneering Parkinson’s monitoring device into new markets. NICE’s positive evaluation and recommendation, which supports NHS use of PDMonitor, was a big endorsement for our business and technology."
The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.
"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
